Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy.
Arthritis, rheumatoid
Inflammatory bowel disease
Neoplasms
Tumor necrosis factor inhibitor
Journal
Intestinal research
ISSN: 1598-9100
Titre abrégé: Intest Res
Pays: Korea (South)
ID NLM: 101572802
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
05
11
2019
accepted:
22
12
2019
pubmed:
8
4
2020
medline:
8
4
2020
entrez:
8
4
2020
Statut:
ppublish
Résumé
Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without concurrent TNFi use. Chart reviews were performed between 1996 and 2015 at the VA North Texas Healthcare System. Cases were patients with inflammatory disease, concomitant malignancy, and TNFi use while controls were patients with inflammatory disease, concomitant malignancy but no TNFi use. Cases and controls were matched for type of malignancy. Analysis was performed with log-rank tests on Kaplan-Meier curves. Thirty-six cases and 72 controls were identified. For cases, survival at 1, 2, and 5 years were 32 (89%), 31 (86%), and 29 (81%) compared to 63 (90%), 61 (87%), and 51 (73%) for the control group (P=0.985). For cases, recurrence rates at 1, 2, and 5 years were 3 (8%), 5 (14%), and 6 (17%) compared to 2 (3%), 5 (7%), and 7 (10%) for the control group (P=0.158). Our findings suggest TNFi may be safely used in select inflammatory disease patients with concurrent cancer if therapy is needed for proper disease control. However, case-by-case consideration in conjunction with an oncologist is recommended while considering the apparent safety of TNFi for patients suffering from active inflammatory diseases despite having a concomitant malignancy.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without concurrent TNFi use.
METHODS
METHODS
Chart reviews were performed between 1996 and 2015 at the VA North Texas Healthcare System. Cases were patients with inflammatory disease, concomitant malignancy, and TNFi use while controls were patients with inflammatory disease, concomitant malignancy but no TNFi use. Cases and controls were matched for type of malignancy. Analysis was performed with log-rank tests on Kaplan-Meier curves.
RESULTS
RESULTS
Thirty-six cases and 72 controls were identified. For cases, survival at 1, 2, and 5 years were 32 (89%), 31 (86%), and 29 (81%) compared to 63 (90%), 61 (87%), and 51 (73%) for the control group (P=0.985). For cases, recurrence rates at 1, 2, and 5 years were 3 (8%), 5 (14%), and 6 (17%) compared to 2 (3%), 5 (7%), and 7 (10%) for the control group (P=0.158).
CONCLUSIONS
CONCLUSIONS
Our findings suggest TNFi may be safely used in select inflammatory disease patients with concurrent cancer if therapy is needed for proper disease control. However, case-by-case consideration in conjunction with an oncologist is recommended while considering the apparent safety of TNFi for patients suffering from active inflammatory diseases despite having a concomitant malignancy.
Identifiants
pubmed: 32252501
pii: ir.2019.09140
doi: 10.5217/ir.2019.09140
pmc: PMC7385568
doi:
Types de publication
Journal Article
Langues
eng
Pagination
282-288Références
Arthritis Res Ther. 2011 Jun 29;13(3):223
pubmed: 21722342
JAMA. 2006 May 17;295(19):2275-85
pubmed: 16705109
Clin Gastroenterol Hepatol. 2016 Jan;14(1):58-64
pubmed: 26247164
Rheumatology (Oxford). 2016 Nov;55(11):2033-2039
pubmed: 27550304
Ann Transplant. 1997;2(4):14-7
pubmed: 9869873
Arthritis Rheumatol. 2016 Oct;68(10):2403-11
pubmed: 27159030
J Clin Gastroenterol. 2019 Jan;53(1):e1-e11
pubmed: 28737645
Inflamm Bowel Dis. 2016 Jun;22(6):1362-9
pubmed: 26919458
Arthritis Rheum. 2011 Jul;63(7):1812-22
pubmed: 21305513
Gastroenterology. 2016 Jul;151(1):22-4
pubmed: 27215661